a public good project by the
Synthesis
Company
of California

© 2026

Balázs Halmos | doi.page

0 works0 citations0 h-index

Balázs Halmos

Montefiore Medical Center(US)HUN-REN Wigner Research Centre for Physics(HU)Tampere University(FI)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Colorectal Cancer Treatments and Studies

Most-Cited Works

→ EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib(2005)3,917 cited
→ Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer(2018)3,583 cited
→ Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers(2012)1,320 cited
→ Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer(2012)1,207 cited
→ Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System(2020)800 cited
→ A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407(2020)635 cited

→ Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib(2006)

583 cited

→ Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia(2004)509 cited

→ BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations(2007)488 cited

→ Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study(2023)465 cited